Development of an HPLC-MS/MS Method for Quantitative Determination of Rivaroxaban in Human Blood Serum

T. A. Rodina; E. S. Mel’nikov; A. A. Aksenov; S. A. Belkov; A. V. Sokolov; A. B. Prokof’ev; G. V. Ramenskaya

doi:10.1007/s11094-018-1824-3

Development of an HPLC-MS/MS Method for Quantitative Determination of Rivaroxaban in Human Blood Serum

Authors: Rodina T.A.¹, Mel’nikov E.S.¹, Aksenov A.A.¹, Belkov S.A.¹, Sokolov A.V.¹, Prokof’ev A.B.¹, Ramenskaya G.V.¹
Affiliations:
1. Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Issue: Vol 52, No 4 (2018)
Pages: 372-377
Section: Article
URL: https://journals.rcsi.science/0091-150X/article/view/245191
DOI: https://doi.org/10.1007/s11094-018-1824-3
ID: 245191

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Statistics

Abstract

An HPLC-MS/MS method for determination of rivaroxaban in human blood serum was developed. Sample preparation included protein precipitation by MeOH followed by centrifugation and dilution with deionized H₂O. The developed procedure had simple sample preparation, a short analysis time, and a wide analytical range (1.00 to 1,000.00 ng/mL). The procedure was convenient for routine bioanalytical studies, in particular, for therapeutic drug monitoring.